Wednesday, Oct. 21, 2026

Tuesday, Oct. 20, 2026

Doctors ask White House to send back FDA's peptide plan

Also in this issue: Mercer says 6% of big employers dropped GLP-1 coverage

Forwarded this? Get it weekday mornings.

Take

Until OMB acts, we wouldn't sign a peptide supply contract or buy a peptide ad. The plan rests on 8-6 advisory votes. Organized doctors now want OMB to reject it, and OMB has no deadline. We think waiting a few weeks loses very little, while building now is a risky bet.

Doctors for America asked OMB on Friday to return FDA's "Interim Access Policy for Compounding Using Certain Peptides." It also wants OMB to clear no enforcement-discretion policy for a substance FDA hasn't put in Category 1. The group names BPC-157, TB-500, KPV, MOTS-c, Epitalon and Semax as the peptides at issue. Its sharpest point is about FDA's own staff: "In July, FDA's own scientists recommended that none of the seven peptides reviewed be added to the compounding list." The advisory committee overrode them 8-6, and their vote is only a recommendation. DFA adds that one newly appointed committee member runs an anti-aging clinic that sells a BPC-157 product for $149.

Meanwhile, the American Academy of Peptide Medicine holds the only meeting on the calendar. It has booked time with reviewers Wednesday at 3 p.m., per OIRA's meeting log. The plan's text isn't public. The only account of what it would allow came from AP last week. Pharmacies could compound popular peptides such as BPC-157 for a while without FDA coming after them. That is enforcement discretion, and FDA can take it back as easily as it grants it.

The review record still says Pending Review. Its legal-deadline field reads "None."

The Signal

Other stories in this issue

Telehealth

One in nine large employers has dropped GLP-1 weight-loss coverage or is weighing it

Employers settle next year's drug coverage this year, so cuts show up in surveys long before a patient sees a denial. Mercer asked 481 large employers this spring. Six percent had already dropped GLP-1 weight-loss coverage for 2026. Another 5% planned to drop it in 2027 or were seriously considering it. And 27% had tightened limits on use or planned to. Vox names PepsiCo, Starbucks and Lowe's among the brands cutting back. The odder number comes from Massachusetts, where commercially insured GLP-1 users fell by half between 2025 and the first quarter of this year. Many of those patients will try to pay cash. In January they will compare your monthly all-in with LillyDirect's $299 starting price on the board below.

Source: Mercer

Telehealth

In a photo study, 54 of 83 compounded GLP-1 users said they were on a brand

University of Michigan researchers had 322 weekly semaglutide and tirzepatide users upload a picture of the label. Coders classed 83 as compounded, Medscape writes. The authors warn that "reliance on self-report alone may not reliably classify medication type." Nobody checked the photos against lab tests. Clinics that take transfer patients can ask for the same photo with one upload field.

Source: Medscape

Prescriber

FDA inspectors found research-only ingredient paperwork at a pharmacy that just recalled tirzepatide

Medical Daily reports that Houston RX recalled 64 vials of compounded tirzepatide in September for a lack of assurance of sterility. An August FDA inspection there produced a Form 483 with 14 observations. The certificates for its tirzepatide and semaglutide ingredients were marked for research and development only. A 483 lists what inspectors saw, and FDA hasn't made a final finding. USA Today covered a second tirzepatide recall from Apothecary Pharma. FDA sent that company a warning letter last December. Before your next vial order, ask your pharmacy for its most recent inspection report.

Source: Medical Daily

Everyone

Confido Health raised $12.5 million to sell AI front desks through private equity

Z47 led the extension, which brings Confido's Series A to $22.5 million, Inc42 says. Confido sells through PE firms, which introduce it to their portfolio companies. Healthcare PE investor Justin Saks joined as a board adviser. If your platform has a PE sponsor, the pitch may come from the sponsor.

Source: Inc42

Medspa

Fresh Clinics bought Spakinect, the good-faith-exam network

Spakinect says it has run more than 1.56 million exams in 40 states, AmSpa reports. Terms weren't disclosed.

Source: AmSpa

The Price Board

Cash GLP-1 prices

Checked .

EdenCompounded
Semaglutide
$99
Tirzepatide
$129

Medication and visits

Strut HealthCompounded
Semaglutide
$129
Tirzepatide
Not listed

Medication and visits

OrderlyMedsCompounded
Semaglutide
$149
Tirzepatide
$299

Medication and visits

DirectMedsCompounded
Semaglutide
$297
Tirzepatide
$399

Medication and visits

LillyDirectBrand: Zepbound vials
Semaglutide
Not listed
Tirzepatide
$299 to $449

Medication only

Wire

In brief

  • The EMA's drug committee recommended Lilly's Foundayo pill, CNBC reports. The European Commission still has to sign off.
  • Allara raised $30 million for insurance-covered virtual women's care. GLP-1s and perimenopause HRT are on the menu.
  • Metabolic Supply Group connects med spas and telehealth practices to compounding pharmacies. It adds lab ordering for its network on Nov. 15 and hasn't named the lab partner.

Dates

Coming up

Share and reply

Forward this to whoever signs your pharmacy contracts. One question, answerable with a number: what's the lowest monthly all-in your clinic charges for compounded semaglutide?

Optimized Daily Report is business news for clinic operators. Not medical, legal, or investment advice. Company claims are the company's.

See the original email on Beehiiv.